What does the evidence say about Kiwi Constipation Randomized Trial?

Updated July 2026

Quick Answer

Kiwi Constipation Randomized Trial has evidence relevant to benefits, uncertainty, and practical interpretation, but conclusions should stay close to the cited sources. One representative finding is: Significant improvements in overall IBS symptom severity were observed ( P P P P P P Conclusion While further research is needed, this is a promising first report that enzymatic digestion may have the potential to decrease the burden of disorders of the gut-brain interaction, including IBS.

Key Takeaways

  • 01Significant improvements in overall IBS symptom severity were observed ( P P P P P P Conclusion While further research is needed, this is a promising first report that enzymatic digestion may have the potential to decrease the burden of disorders of the gut-brain interaction, including IBS. [Kaye AJ (2026)]
  • 02Background and aims Irritable bowel syndrome (IBS) is a highly prevalent and morbid condition that causes tremendous symptom burden, impacts quality of life, and generates substantial healthcare costs. [Kaye AJ (2026)]
  • 03Current therapies are challenging to utilize and do not provide relief to many patients, creating a clear need for new innovation. [Kaye AJ (2026)]
  • 04Among dietary interventions, the most consistent clinical evidence supports the use of soluble fiber (e.g., psyllium), kiwifruit or prunes, and magnesium- or sulfate-rich mineral waters to improve stool frequency and consistency. [Ribichini E (2026)]
The current Migaku evidence database contains 2 reusable source documents for Kiwi Constipation Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Significant improvements in overall IBS symptom severity were observed ( P P P P P P Conclusion While further research is needed, this is a promising first report that enzymatic digestion may have the potential to decrease the burden of disorders of the gut-brain interaction, including IBS. [Kaye AJ (2026); evidence level 3] - Background and aims Irritable bowel syndrome (IBS) is a highly prevalent and morbid condition that causes tremendous symptom burden, impacts quality of life, and generates substantial healthcare costs. [Kaye AJ (2026); evidence level 3] - Current therapies are challenging to utilize and do not provide relief to many patients, creating a clear need for new innovation. [Kaye AJ (2026); evidence level 3] - Among dietary interventions, the most consistent clinical evidence supports the use of soluble fiber (e.g., psyllium), kiwifruit or prunes, and magnesium- or sulfate-rich mineral waters to improve stool frequency and consistency. [Ribichini E (2026); evidence level 4] - Chronic constipation (CC) is a common disorder of gut-brain interaction that markedly impairs quality of life and remains challenging to manage. [Ribichini E (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. FODMAP-Targeting Digestive Enzyme Blend for Management of Gastrointestinal Symptoms: A "Real-World" Pre-Post Intervention Cohort Study.
  2. Dietary strategies for chronic constipation: smartly targeting hormonal and reflex pathways for optimal recovery.